

# Sigurdur Yngvi Kristinsson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4772405/sigurdur-yngvi-kristinsson-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137  
papers

7,977  
citations

47  
h-index

88  
g-index

143  
ext. papers

9,569  
ext. citations

4.8  
avg. IF

5.57  
L-index

#	Paper	IF	Citations
137	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e538-48	21.7	2253
136	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. <i>Haematologica</i> , <b>2015</b> , 100, 107-13	6.6	250
135	Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1993-9	2.2	244
134	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. <i>Blood</i> , <b>2010</b> , 116, 5501-6	2.2	224
133	Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. <i>Blood</i> , <b>2008</b> , 112, 2199-204	2.2	194
132	Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2897-903	2.2	189
131	Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2410-5	2.2	179
130	Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. <i>Haematologica</i> , <b>2014</b> , 99, 392-8	6.6	165
129	Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2514-20	2.2	159
128	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , <b>2010</b> , 115, 4991-8	2.2	158
127	Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 830-4	2.2	144
126	Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2995-3001	2.2	141
125	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). <i>Blood</i> , <b>2011</b> , 118, 4086-92	2.2	136
124	Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. <i>Blood</i> , <b>2008</b> , 112, 3582-6	2.2	136
123	Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. <i>Blood</i> , <b>2008</b> , 112, 3052-6	2.2	127
122	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. <i>Blood</i> , <b>2011</b> , 117, 5573-81	2.2	125
121	Autoimmunity and the risk of myeloproliferative neoplasms. <i>Haematologica</i> , <b>2010</b> , 95, 1216-20	6.6	123

120	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. <i>Blood</i> , <b>2009</b> , 114, 791-5 <sup>2.2</sup>	112
119	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, 317-325	8 101
118	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , <b>2016</b> , 7, 12050	17.4 101
117	Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. <i>Blood</i> , <b>2009</b> , 113, 3666-72	2.2 99
116	Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2009</b> , 94, 647-53	6.6 99
115	Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. <i>International Journal of Cancer</i> , <b>2007</b> , 121, 2260-6	7.5 96
114	Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. <i>Mayo Clinic Proceedings</i> , <b>2010</b> , 85, 225-30 <sup>6.4</sup>	93
113	Second malignancies after multiple myeloma: from 1960s to 2010s. <i>Blood</i> , <b>2012</b> , 119, 2731-7	2.2 87
112	Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2288-95	2.2 84
111	Cancer risk among patients with myotonic muscular dystrophy. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 2480-6	27.4 82
110	Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. <i>Blood</i> , <b>2010</b> , 116, 2651-5	2.2 81
109	Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. <i>Blood</i> , <b>2014</b> , 123, 338-45	2.2 78
108	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. <i>Haematologica</i> , <b>2012</b> , 97, 854-8	6.6 77
107	Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 557-67	9.7 74
106	Thrombosis in multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , <b>2010</b> , 2010, 437-44	3.1 71
105	Highly increased familial risks for specific lymphoma subtypes. <i>British Journal of Haematology</i> , <b>2009</b> , 146, 91-4	4.5 71
104	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. <i>Haematologica</i> , <b>2009</b> , 94, 1714-20	6.6 70
103	The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 168-74	13.4 67

102	Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. <i>Blood</i> , <b>2012</b> , 119, 990-6	2.2	66
101	Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. <i>Gastroenterology</i> , <b>2009</b> , 136, 91-8	13.3	64
100	Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. <i>Haematologica</i> , <b>2018</b> , 103, 506-513	6.6	64
99	Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. <i>Haematologica</i> , <b>2009</b> , 94, 1259-65	6.6	62
98	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. <i>Haematologica</i> , <b>2018</b> , 103, e412-e415	6.6	58
97	Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. <i>Blood</i> , <b>2011</b> , 118, 6284-91	2.2	58
96	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , <b>2018</b> , 9, 3707	17.4	57
95	Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 2147-50	7.5	55
94	Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. <i>Nature Communications</i> , <b>2015</b> , 6, 7213	17.4	54
93	Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 60-5	7.1	51
92	A population-based assessment of mortality and morbidity patterns among patients with thymoma. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 2688-94	7.5	49
91	Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in Sweden. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2073-80	2.2	47
90	Thrombosis is associated with inferior survival in multiple myeloma. <i>Haematologica</i> , <b>2012</b> , 97, 1603-7	6.6	46
89	Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. <i>Leukemia</i> , <b>2018</b> , 32, 2203-2210	10.7	43
88	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1293-1301	13.4	33
87	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , <b>2021</b> , 22, e105-e118	21.7	32
86	Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 179-83	2.2	30
85	Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. <i>Haematologica</i> , <b>2009</b> , 94, 1581-9	6.6	28

84	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. <i>Expert Review of Molecular Diagnostics</i> , <b>2011</b> , 11, 593-603	3.8	26
83	Incidence of multiple myeloma in Great Britain, Sweden, and Malm�Sweden: the impact of differences in case ascertainment on observed incidence trends. <i>BMJ Open</i> , <b>2016</b> , 6, e009584	3	23
82	Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 337-44	2.2	23
81	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. <i>Blood Advances</i> , <b>2017</b> , 1, 2186-2192	7.8	23
80	No familial aggregation in chronic myeloid leukemia. <i>Blood</i> , <b>2013</b> , 122, 460-1	2.2	21
79	Novel aspects pertaining to the relationship of Waldenstr�'s macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9, 19-22		20
78	Autoimmunity and risk for Hodgkin's lymphoma by subtype. <i>Haematologica</i> , <b>2009</b> , 94, 1468-9	6.6	20
77	Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 216-222	3.8	19
76	Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 918-24	4.5	18
75	Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e79851	3.7	18
74	Population-based study on the impact of the familial form of Waldenstr�' macroglobulinemia on overall survival. <i>Blood</i> , <b>2015</b> , 125, 2174-5	2.2	17
73	Timing of births and endometrial cancer risk in Swedish women. <i>Cancer Causes and Control</i> , <b>2009</b> , 20, 1441-9	2.8	17
72	Prior history of non-melanoma skin cancer is associated with increased mortality in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2009</b> , 94, 1460-4	6.6	17
71	Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. <i>Haematologica</i> , <b>2016</b> , 101, e145-8	6.6	16
70	Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. <i>Blood Advances</i> , <b>2017</b> , 1, 2790-2798	7.8	16
69	Familial aggregation of lymphoplasmacytic lymphoma/Waldenstr�' macroglobulinemia with solid tumors and myeloid malignancies. <i>Acta Haematologica</i> , <b>2012</b> , 127, 173-7	2.7	16
68	History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. <i>Annals of Hematology</i> , <b>2017</b> , 96, 261-269	3	14
67	The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. <i>Blood Advances</i> , <b>2017</b> , 1, 2392-2398	7.8	14

66	Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , <b>2009</b> , 94, 1179-81	6.6	14
65	Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5081-7	2.2	13
64	Fractures and survival in multiple myeloma: results from a population-based study. <i>Haematologica</i> , <b>2020</b> , 105, 1067-1073	6.6	12
63	Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. <i>Cancer Medicine</i> , <b>2015</b> , 4, 147-54	4.8	11
62	Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9, 23-6		11
61	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 94	7	11
60	Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study. <i>Annals of Hematology</i> , <b>2016</b> , 95, 871-9	3	11
59	Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance. <i>Seminars in Hematology</i> , <b>2011</b> , 48, 46-54	4	10
58	Epidemiology of hairy cell leukemia in Iceland. <i>The Hematology Journal</i> , <b>2002</b> , 3, 145-7		10
57	Dietary intake is associated with risk of multiple myeloma and its precursor disease. <i>PLoS ONE</i> , <b>2018</b> , 13, e0206047	3.7	10
56	Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 194-7	2	9
55	Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 2208-9	7.5	9
54	Hodgkin lymphoma risk following infectious and chronic inflammatory diseases: a large population-based case-control study from Sweden. <i>International Journal of Hematology</i> , <b>2015</b> , 101, 563-8 <sup>2,3</sup>		8
53	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 268	8	8
52	Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 187-90	2	8
51	Survival in patients with familial and sporadic myeloproliferative neoplasms. <i>Blood</i> , <b>2015</b> , 125, 3665-6	2.2	8
50	Infection in infancy and subsequent risk of developing lymphoma in children and young adults. <i>Blood</i> , <b>2011</b> , 117, 1670-2	2.2	8
49	What causes Waldenström's macroglobulinemia: genetic or immune-related factors, or a combination?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11, 85-7	2	7

48	Risk of Arterial and Venous Thrombosis in 11,155 Patients with Myeloproliferative Neoplasms and 44,620 Matched Controls; A Population-Based Study. <i>Blood</i> , <b>2014</b> , 124, 632-632	2.2	7
47	Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients. <i>Annals of Hematology</i> , <b>2010</b> , 89, 523-5	3	6
46	Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors. <i>Thrombosis Research</i> , <b>2020</b> , 186, 86-92	8.2	6
45	Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. <i>Genome Medicine</i> , <b>2009</b> , 1, 55	14.4	5
44	Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls. <i>Haematologica</i> , <b>2020</b> , 105, 2679-2681	6.6	4
43	Increased Risks of Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF) among 24577 First-Degree Relatives of 11039 Patients with Chronic Myeloproliferative Disorders (MPD) in Sweden.. <i>Blood</i> , <b>2007</b> , 110, 680-680	2.2	4
42	Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2009</b> , 15, 473-8	2.2	3
41	Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011. <i>Blood</i> , <b>2013</b> , 122, 1972-1972	2.2	3
40	Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 376-382	3.8	3
39	Comorbidities in multiple myeloma and implications on survival: A population-based study. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 774-782	3.8	3
38	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 275-282	3.8	3
37	Illness severity and risk of mental morbidities among patients recovering from COVID-19: a cross-sectional study in the Icelandic population. <i>BMJ Open</i> , <b>2021</b> , 11, e049967	3	3
36	A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 346-353	3.8	3
35	Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups. <i>Acta Haematologica</i> , <b>2015</b> , 133, 372-380	2.7	2
34	A 'pilot' study on air-travel and venous thromboembolism. <i>British Journal of Haematology</i> , <b>2009</b> , 146, 457-9	4.5	2
33	Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.. <i>Blood</i> , <b>2009</b> , 114, 1872-1872	2.2	2
32	Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients. <i>Blood</i> , <b>2012</b> , 120, 945-945	2.2	2
31	Bone Marrow Fibrosis In Patients With Multiple Myeloma: A New Prognostic Factor For Survival?. <i>Blood</i> , <b>2013</b> , 122, 1946-1946	2.2	2

30	Validity of chronic disease diagnoses in Icelandic healthcare registries.. <i>Scandinavian Journal of Public Health</i> , <b>2021</b> , 14034948211059974	3	2
29	The association of cancer and venous thrombosis: yes, Trousseau is right...again!. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 734-5	1.9	1
28	Response: More on disease anticipation in familial MPN. <i>Blood</i> , <b>2008</b> , 112, 2588-2589	2.2	1
27	Prognosis in Acute Myeloid Leukemia: A Population-Based Study on 5,809 Patients Diagnosed in Sweden 1973-2001.. <i>Blood</i> , <b>2005</b> , 106, 1845-1845	2.2	1
26	Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 380-388	3.8	1
25	A population-based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 547-554	2.8	0
24	The Success Story of Targeted Therapy In Chronic Myeloid Leukemia: A Population-Based Study of 3,173 Patients Diagnosed In Sweden 1973-2008. <i>Blood</i> , <b>2010</b> , 116, 205-205	2.2	0
23	Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 191	7	0
22	Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 137-144	3.8	0
21	Genetic variants associated with platelet count are predictive of human disease and physiological markers. <i>Communications Biology</i> , <b>2021</b> , 4, 1132	6.7	0
20	Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 876271	8.4	0
19	Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. <i>British Journal of Haematology</i> , <b>2019</b> , 186, 37-44	4.5	
18	Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) <b>2017</b> , 143-167		
17	Epidemiology of Waldenström Macroglobulinemia <b>2017</b> , 97-109		
16	Re: Risk of malignancy associated with Lyme disease: Still up in the air. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 2718-2718	7.5	
15	Genetics in Lymphomagenesis <b>2013</b> , 835-847		
14	Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls. <i>Blood</i> , <b>2020</b> , 136, 44-45	2.2	
13	Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM). <i>Blood</i> , <b>2021</b> , 138, 154-154	2.2	



- 12 Patterns of Venous Thromboembolism (VTE) Following Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM) among 4 Million U.S. Veterans.. *Blood*, **2006**, 108, 4998-4998 2,3
- 11 Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden.. *Blood*, **2007**, 110, 660-660 2.2
- 10 Peripheral Neuropathy Is Associated with an Increased Risk of Fractures in Individuals with Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study Including 15,351 MGUS Cases. *Blood*, **2018**, 132, 1914-1914 2.2
- 9 The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study. *Blood*, **2018**, 132, 4490-4490 2.2
- 8 Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases. *Blood*, **2019**, 134, 5444-5444 2.2
- 7 The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study. *Blood*, **2016**, 128, 3246-3246 2.2
- 6 Immune-Related and Inflammatory Conditions Likely Play a Role in the Development of Lymphoplasmacytic Lymphoma/Waldenstro m $\bar{m}$  Macroglobulinemia. *Blood*, **2008**, 112, 3758-3758 2.2
- 5 Improved Patient Survival and Cure for Hodgkin Lymphoma: A Population-Based Study of 6,136 Patients Diagnosed in Sweden 1973-2005.. *Blood*, **2009**, 114, 1553-1553 2.2
- 4 Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study. *Blood*, **2010**, 116, 4053-4053 2.2
- 3 Monoclonal Gammopathy Of Undetermined Significance and Risk Of Lymphoid and Myeloid Malignancies: 743 Cases Followed For Up To 30 Years In Sweden. *Blood*, **2013**, 122, 3124-3124 2.2
- 2 Multiple Myeloma Patients With Prior Knowledge Of MGUS Have a Better Survival Compared To Multiple Myeloma Patients Without Prior Knowledge Of MGUS. *Blood*, **2013**, 122, 1984-1984 2.2
- 1 Impact Of History Of Autoimmune Disease On Survival In Multiple Myeloma and Monoclonal Gammopathy Of Undetermined Significance: A Population-Based Study. *Blood*, **2013**, 122, 1898-1898 2.2